

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7935286

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	VANCE M. THOMPSON	04/20/2021
RECEIVING PARTY DATA		
Name:	TEAROPTIX, INC.	
Street Address:	801 HERMOSA WAY	
City:	MENLO PARK	
State/Country:	CALIFORNIA	
Postal Code:	94025	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	18142699	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	jborrego@merchantgould.com	
Correspondent Name:	MERCHANT & GOULD P.C.	
Address Line 1:	P.O. BOX 2903	
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402-0903	
ATTORNEY DOCKET NUMBER:	18899.0008USC5	
NAME OF SUBMITTER:	KRISTEN M. GEARY	
SIGNATURE:	/Kristen M. Geary/	
DATE SIGNED:	05/04/2023	
Total Attachments: 4		
source=2023_05_04_ASSGNMT_18899_0008USC5#page1.tif		
source=2023_05_04_ASSGNMT_18899_0008USC5#page2.tif		
source=2023_05_04_ASSGNMT_18899_0008USC5#page3.tif		
source=2023_05_04_ASSGNMT_18899_0008USC5#page4.tif		

ASSIGNMENT

This Patent Assignment (this "ASSIGNMENT") is by and between Vance M. Thompson, (hereinafter referred to as the "ASSIGNOR"), and TearOptix, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware and having an office and place of business at 801 Hermosa Way, Menlo Park, California 94025 (hereinafter "ASSIGNEE").

RECITALS

WHEREAS ASSIGNOR previously acquired the following patents listed in the attached Schedule;

AND WHEREAS ASSIGNEE is desirous of acquiring the entire right, title and interest in and to said inventions, improvements and application(s) identified above and in and to the Letters Patent(s) to be obtained therefor in any country;

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable considerations, the receipt and sufficiency whereof is hereby acknowledged, we have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto said ASSIGNEE, its successors or assigns, the entire right, title and interest for all countries in and to all inventions and improvements disclosed in the aforesaid application, and the right(s) to claim priority thereto, and in and to the application, all patent applications based upon said application, all divisions, continuations, or renewals thereof, all Letters Patent which may be granted therefrom, and all reissues or extensions of such patents, and in and to any and all applications which have been or shall be filed in any foreign countries for Letters Patent on the inventions and improvements, including an assignment of all rights under the provisions of the International Convention, and all Letters Patent of foreign countries which may be granted therefrom; and we do hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all United States Letters Patent for the aforesaid inventions and improvements to the ASSIGNEE as the assignee of the entire right, title and interest in and to the same, for the use of the ASSIGNEE, its successors and assigns.

AND, for the consideration aforesaid, we do hereby agree that we and our executors and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said ASSIGNEE, its successors and representatives all facts known to us relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said ASSIGNEE, its successors or assigns the entire right, title and interest in and to the improvements, inventions, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby sold, assigned and conveyed, or intended so to be.

AND, furthermore we covenant and agree with said ASSIGNEE, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by us and that full right to convey the same as herein expressed is possessed by us.

Date 4/20/21 By Vance M. Thompson
(Signature)

Name: Vance M. Thompson

Date _____ By _____
(Signature)

Name: Vartan Ghazarossian

Title: President, CEO
TearOptix, Inc.

AND, for the consideration aforesaid, we do hereby agree that we and our executors and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said ASSIGNEE, its successors and representatives all facts known to us relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said ASSIGNEE, its successors or assigns the entire right, title and interest in and to the improvements, inventions, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby sold, assigned and conveyed, or intended so to be.

AND, furthermore we covenant and agree with said ASSIGNEE, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by us and that full right to convey the same as herein expressed is possessed by us.

Date _____

By _____
(Signature)

Name: Vance M. Thompson

Date April 20, 2021

By Vartan Ghazarossian
(Signature)

Name: Vartan Ghazarossian

Title: President, CEO
TearOptix, Inc.

SCHEDULE

Attorney Ref	Country	App No.	App Date	Patent No.	Grant Date
18909.0001US01	US	14/071240	11/04/2013	9668916	06/06/2017
18909.0001USC1	US	15/608503	05/30/2017	10449086	10/22/2019
18909.0001USC2	US	15/827582	11/30/2017	10548767	02/04/2020
18909.0001USC3	US	16/777358	01/30/2020		
18909.0001WO01	WO	PCT/US2014/063696	11/03/2014		